The Food and Drug Administration will no longer approve COVID-19 vaccines for healthy people under 65 without rigorous trials.

SHELTON, CT / ACCESS Newswire / May 22, 2025 / Dr. Anil Diwan, President of NanoViricides, Inc. (NYSE Amer.:NNVC ) (the “Company”), comments on the new COVID Vaccine policy adopted by the US FDA. The new FDA COVID Vaccine Booster Shots policy [1] is based on the findings that the groups that benefit from repeat

The U.S. Food and Drug Administration's advisory panel is set to vote on Thursday to recommend whether COVID-19 vaccines for the 2025-2026 immunization campaign should target strains of the virus descending from the JN.

Healthy and under the age of 65? You might not need to receive an annual COVID-19 booster. What to know about new guidelines.

The Food and Drug Administration (FDA) vaccine advisory group today recommended sticking with a monovalent JN.1 lineage vaccine for COVID vaccines for the upcoming US respiratory virus season, though the experts didn't recommend a specific sublineage.

Advisers to the U.S. Food and Drug Administration on Thursday unanimously voted in favor of recommending that COVID-19 vaccines for 2025-26 should target newer strains of the JN.1 variant.

FDA FLAGS SEVERE ITCH — Patients who stop using the oral allergy medicines cetirizine (Zyrtec) or levocetirizine (Xyzal) may experience rare but severe itching after longtime use, the FDA has cautioned.

President Donald Trump’s administration is slated to lay out its approach to Covid vaccination at an event Tuesday that could spell major changes in what is required to get regulatory approval for immunizations.